NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Cell Therapy Group

Shanghai Cell Therapy Group

Private
ShanghaiHealthcare & Life Scienceshttp://shcell.com/

Last Round

Series D

Dec 6, 2021

Est. Valuation

$1.12B

Total Funding Raised

$278.33M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Shanghai Cell Therapy Group is a biotechnology company that develops cell therapy products and provides related services for cancer and age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2C

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cell therapycell bankingCAR-T therapyoncology servicescancer treatmentimmune cell bankingstem cell bankingprecision medicineclinical trialssolid tumor therapygene writinggene editingnanobody technologyregenerative medicineanti-aging therapyAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Cell Therapy Group Comparables

Compare Shanghai Cell Therapy Group with similar companies based on industry and business-model similarity.

Shanghai Cell Therapy Group comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vcanbio Cell & Gene Engineering Corporation
75%
Shenzhen Beike Biotechnology Co., Ltd.
66%
JW Therapeutics
59%

Shanghai Cell Therapy Group Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DDec 6, 2021
Series DMar 23, 2021
Series CDec 17, 2018
Series BApr 19, 2016
Series AJun 3, 2014

Shanghai Cell Therapy Group Investors

Notable investors and investment history

Shanghai Cell Therapy Group investors
InvestorRounds
GF Xinde Investment ManagementSeries D
Legend CapitalSeries C, Series B
CCB InternationalSeries D
怀格资本Series D
Jiuzhou VentureSeries D
China Industrial Asset Management LimitedSeries C
Haier CapitalSeries D, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 28, 2.2x the trailing average.

  • Jun 21, 2026

    Monthly visitors grew 116% MoM.

Shanghai Cell Therapy Group Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Cell Therapy Group Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Cell Therapy Group's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range94
Year Founded2013
Last FundingDec 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.